CN103764847B - 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法 - Google Patents

对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法 Download PDF

Info

Publication number
CN103764847B
CN103764847B CN201280040055.4A CN201280040055A CN103764847B CN 103764847 B CN103764847 B CN 103764847B CN 201280040055 A CN201280040055 A CN 201280040055A CN 103764847 B CN103764847 B CN 103764847B
Authority
CN
China
Prior art keywords
colorectal cancer
kras gene
chemotherapy
mutation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280040055.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103764847A (zh
Inventor
伊藤雅信
冈部博之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN103764847A publication Critical patent/CN103764847A/zh
Application granted granted Critical
Publication of CN103764847B publication Critical patent/CN103764847B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CN201280040055.4A 2011-08-16 2012-08-15 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法 Active CN103764847B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-177838 2011-08-16
JP2011177838 2011-08-16
PCT/JP2012/070745 WO2013024865A1 (ja) 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法

Publications (2)

Publication Number Publication Date
CN103764847A CN103764847A (zh) 2014-04-30
CN103764847B true CN103764847B (zh) 2016-05-11

Family

ID=47715182

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280040055.4A Active CN103764847B (zh) 2011-08-16 2012-08-15 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法

Country Status (21)

Country Link
US (1) US9371380B2 (enExample)
EP (1) EP2746404B1 (enExample)
JP (1) JP5832541B2 (enExample)
KR (1) KR101693090B1 (enExample)
CN (1) CN103764847B (enExample)
AU (1) AU2012295841B2 (enExample)
CY (1) CY1119869T1 (enExample)
DK (1) DK2746404T3 (enExample)
ES (1) ES2659264T3 (enExample)
HR (1) HRP20180130T1 (enExample)
HU (1) HUE035347T2 (enExample)
LT (1) LT2746404T (enExample)
NO (1) NO2746404T3 (enExample)
PL (1) PL2746404T3 (enExample)
PT (1) PT2746404T (enExample)
RS (1) RS56911B1 (enExample)
RU (1) RU2585528C2 (enExample)
SI (1) SI2746404T1 (enExample)
SM (1) SMT201800108T1 (enExample)
TW (1) TWI550089B (enExample)
WO (1) WO2013024865A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
UA123403C2 (uk) * 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
AU2017397458B2 (en) * 2017-02-01 2025-07-10 Modernatx, Inc. RNA cancer vaccines
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107001A (zh) * 2005-01-26 2008-01-16 大鹏药品工业株式会社 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1849470T5 (pl) 2005-01-26 2024-06-10 Taiho Pharmaceutical Co., Ltd. Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107001A (zh) * 2005-01-26 2008-01-16 大鹏药品工业株式会社 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Colorectal cancer promising results with phaseII TAS-102;Benoit Samson;《Oncology exchange》;20120229;第11卷(第1期);28-29 *
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines;Irene V. Bijnsdorp,et al;《Cancer Sci》;20100228;第101卷;440–447 *
TAS-102: more than an antimetabolite;Godefridus J Peters, Irene V Bijnsdorp;《Lacet Oncol》;20121231;第13卷;e518-519 *

Also Published As

Publication number Publication date
JPWO2013024865A1 (ja) 2015-03-05
JP5832541B2 (ja) 2015-12-16
ES2659264T3 (es) 2018-03-14
NO2746404T3 (enExample) 2018-05-05
TW201319257A (zh) 2013-05-16
WO2013024865A1 (ja) 2013-02-21
RU2585528C2 (ru) 2016-05-27
TWI550089B (zh) 2016-09-21
EP2746404B1 (en) 2017-12-06
EP2746404A1 (en) 2014-06-25
SMT201800108T1 (it) 2018-05-02
RU2014109999A (ru) 2015-10-10
SI2746404T1 (en) 2018-04-30
DK2746404T3 (en) 2018-01-15
CY1119869T1 (el) 2018-06-27
HK1197086A1 (zh) 2015-01-02
HRP20180130T1 (hr) 2018-04-06
HUE035347T2 (en) 2018-05-02
PT2746404T (pt) 2018-01-10
PL2746404T3 (pl) 2018-04-30
CN103764847A (zh) 2014-04-30
KR20140057328A (ko) 2014-05-12
AU2012295841B2 (en) 2015-12-10
RS56911B1 (sr) 2018-05-31
EP2746404A4 (en) 2015-04-08
US9371380B2 (en) 2016-06-21
AU2012295841A1 (en) 2014-04-03
LT2746404T (lt) 2018-04-25
US20140213602A1 (en) 2014-07-31
KR101693090B1 (ko) 2017-01-04

Similar Documents

Publication Publication Date Title
TW202136252A (zh) 化合物及其用途
EP4308124A1 (en) Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
CA3177444A1 (en) Use of ezh2 inhibitors for treating cancer
CN103764847B (zh) 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法
RS67265B1 (sr) Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c
US8598188B2 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
TWI595879B (zh) Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
JP7334194B2 (ja) Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法
HK1197086B (en) Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
JP5566376B2 (ja) 腎細胞癌に対する化学療法の治療効果予測方法
WO2025075211A1 (en) Alisertib and paclitaxel for treating small cell lung cancer
JPWO2010134588A1 (ja) ジヒドロピリミジン脱水素酵素遺伝子の発現量を指標とした化学療法の治療効果予測方法
EA047636B1 (ru) Соединения и способы их применения
JPWO2010074240A1 (ja) 化学療法の治療効果予測方法
Searle et al. 104th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC, USA-March 6-10, 2013
WO2010074241A1 (ja) 併用化学療法の治療効果予測方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197086

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1197086

Country of ref document: HK